In contrast, higher expression of miR-181a in human DLBCL is associated with improved PFS in patients treated with R-CHOP and it has been shown to target the oncogene FOXP1 in cell lines [41]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.